PATERSON, N.J., April 24 - Amneal Pharmaceuticals, LLC is
pleased to announce the execution of an Asset Purchase Agreement for
Amneal’s wholly-owned subsidiary, Amneal Pharmaceuticals of New York, LLC,
to acquire the assets, facilities and business of Interpharm. The
acquisition includes Interpharm’s facilities on Long Island, New York as
well as the intellectual property including ANDA’s, technology and
processes.
Amneal will use its strong leadership and financial position to fully
realize the potential of Interpharm’s powerful product line, ensure
approval of its well defined development pipeline and leverage the unique
manufacturing capabilities.
“Utilizing Amneal’s financial strength, superb quality management, R&D
and manufacturing expertise with Interpharm’s outstanding facilities,
leading market share and high value pipeline creates tremendous
opportunities for rapid growth and exceptional customer satisfaction,” said
Chintu Patel, CEO of Amneal.
“Interpharm is excited about this acquisition of our assets. The
financial stability brought by Amneal will allow it to springboard its
rapid growth plans, and enhance the value to our loyal trading partners,”
added Jeff Weiss, Interpharm’s executive vice president of sales and
marketing.
Amneal will list assets of over one hundred products approved or filed
with the USFDA and in development, controlled substance (C II-V) licensing
and manufacturing, hormonal production suite, high potency production
suite, soft gelatin capsules manufacturing, liquids manufacturing plant, 20
billion unit oral solid capacity and expansive R&D centers in New Jersey,
New York and newly opened in India. Amneal president Chirag Patel comments,
“This acquisition of intellectual and tangible assets provides Amneal the
ability to accelerate its aggressive growth plans and rapidly broaden and
deepen its product portfolio, while staying committed to full vertical
integration and industry leading operations, R&D and Customer Service.”
About Amneal Pharmaceuticals:
Amneal Pharmaceuticals LLC, headquartered in Paterson, NJ, is a
USA-based firm that develops, manufacturers and distributes generic
pharmaceutical products regulated and approved by the US FDA. Positioned as
“Generic’s New Generation,” the company utilizes diverse R&D and
manufacturing expertise to conceive breakthrough developments with lasting
impact. Vigorous ANDA growth and broad product acquisitions are key
features of Amneal’s strategic growth plan, as is the company’s commitment
to building deep relationships with its customer base. Amneal delivers
superior service levels, quality products, and dynamic value throughout the
pharmaceutical industry.
SOURCE Amneal Pharmaceuticals, LLC